

Japan's Nippon to establish Singapore-based JV to license drugs in Asia

27 August 2025 | News

This joint venture will be established through joint investment by Nippon Kayaku, Formiica, and CBC, with its base in Singapore



Nippon Kayaku, Formiica Pharmaceuticals and CBC Co. have agreed to jointly establish a joint venture (JV) for the purpose of in-licensing pharmaceutical products into Asia including Japan and/or Oceania.

This joint venture will be established through joint investment by Nippon Kayaku, Formiica, and CBC, with its base in Singapore. Its main purpose is to in-licensing pharmaceutical products developed and owned by other companies, and to sublicense such products to countries in Asia and/or Oceania, including Japan.

Nippon Kayaku will have preferential negotiation rights regarding the Japanese territory, enabling Nippon Kayaku to be responsible for development and sales in Japan. This is expected to strengthen Nippon Kayaku's domestic pharmaceutical business and secure stable earnings.

Companies will promptly proceed with the establishment of the joint venture and accelerate the consideration and negotiation of promising in-licensing candidates. By utilising this joint venture, Nippon Kayaku will promote in-licensing strategies that contributes to the company's growth and enhancement of corporate value.

Formiica Pharmaceuticals is a Singapore-based holding company incubated by the SEA Healthcare Fund VCC with Wuxi AppTec and UOBVM as sector advisor and investment advisor respectively.

Founded in 1925, CBC Co., Ltd is a privately-owned, unlisted company headquartered in Tokyo, with a legacy spanning over 100 years. As a leading global trading company, its diverse portfolio includes pharmaceuticals, chemicals, and electronics.